Improved oral nutraceutical-based intervention for the management of obesity: pterostilbene-loaded chitosan nanoparticles

Nanomedicine (Lond). 2022 Jun;17(15):1055-1075. doi: 10.2217/nnm-2022-0158. Epub 2022 Sep 6.

Abstract

Aim: To formulate and assess the oral anti-obesity effect of polymeric-based pterostilbene (PS)-loaded nanoparticles. Methods: Pterostilbene-hydroxypropyl β-cyclodextrin inclusion complex loaded in chitosan nanoparticles (PS/HPβCD-NPs) were prepared and characterized in vitro. Cytotoxicity, pharmacokinetics and anti-obesity effects were assessed on Caco-2 cell line and high-fat-diet-induced obesity rat model, respectively. In vivo assessment included histological examination, protein and gene expression of obesity biomarkers in adipose tissues. Results: Safe PS/HPβCD-NPs were successfully prepared with improved bioavailability compared with free PS. PS/HPβCD-NPs showed an improved anti-obesity effect, as supported by histological examination, lipid profile, UCP1 gene expression and protein expression of SIRT1, COX2, IL-6 and leptin. Conclusion: Orally administered PS nanoparticles represent a new and promising anti-obesity strategy owing to the sustainable weight loss and minimal side effects; this may be of great socio-economic impact.

Keywords: UCP1; chitosan nanoparticles; hydroxypropyl β-cyclodextrin; pharmacokinetics; pterostilbene.

Plain language summary

Weight gain or obesity represents a major health risk and leads to diseases including cancer and heart disease. Most anti-obesity medications have significant side effects, and there are notable challenges concerning their availability in the body to produce an effect. Pterostilbene is a herbal drug with beneficial anti-obesity effects. However, it has problems such as poor solubility which restrict its use. The aim of the study was to formulate pterostilbene in a nano-based delivery system and fully characterize its anti-obesity effect when given orally. We evaluated the safety and anti-obesity effects of pterostilbene nanoparticles in cells and in obese rats fed on a high-fat diet. We also looked at how the body absorbs, distributes and gets rid of these nanoparticles. The prepared nanoparticles were nontoxic, with an improved anti-obesity effect; they decreased cholesterol levels and helped in changing white fat (which stores fat) to brown fat (which burns calories). We conclude that the developed pterostilbene nanoparticles, given orally, are a new and promising anti-obesity strategy given their long-lasting effect on weight loss and the minimal side effects. This may be of great economic and societal impact.

MeSH terms

  • 2-Hydroxypropyl-beta-cyclodextrin / therapeutic use
  • Animals
  • Caco-2 Cells
  • Chitosan*
  • Cyclooxygenase 2
  • Dietary Supplements
  • Interleukin-6
  • Leptin / genetics
  • Leptin / therapeutic use
  • Lipids / therapeutic use
  • Nanoparticles*
  • Obesity / drug therapy
  • Rats
  • Sirtuin 1 / therapeutic use

Substances

  • 2-Hydroxypropyl-beta-cyclodextrin
  • 3,5-dimethoxy-4'-hydroxystilbene
  • Chitosan
  • Cyclooxygenase 2
  • Interleukin-6
  • Leptin
  • Lipids
  • pterostilbene
  • Sirtuin 1